Transfusion of highly purified, allogenic haploidentical KIR-HLA mismatched NK cells following low-dose immunosuppression (with cyclophosphamide and fludarabine) and administration of IL-2 yielded beneficial response rates at low toxicity without GvHD and has been proposed as an innovative alternative consolidation therapy for pediatric and adult AML patients [131,132]. The gene discussed is IL2; the disease is acute myeloid leukemia.